Table 2.

Comparison of MR-imaging features of cHCC-CCA

MRI features	MVI-positive (n = 59)	MVI-negative (n = 60)	p value
Tumor location			0.609
Left liver lobe	13 (22)	13 (21.7)
Right liver lobe	46 (78)	46 (76.7)
Other location	0 (0)	1 (1.6)
Shape			0.672
Globular	28 (47.5)	32 (53.4)
Lobulated	13 (22)	14 (23.3)
Irregular	18 (30.5)	14 (23.3)
Margin			0.013*
Smooth	20 (33.9)	34 (56.7)
Non-smooth	39 (66.1)	20 (43.3)
Intratumoral hemorrhage			0.872
Absent	45 (76.3)	45 (75)
Present	14 (23.7)	15 (25)
Fat deposition			0.134
Absent	53 (89.8)	58 (96.7)
Present	6 (10.2)	2 (3.3)
Intratumoral necrosis			0.313
Absent	32 (54.2)	38 (63.3)
Present	27 (45.8)	22 (36.7)
Non-rim APHE			0.296
Absent	38 (64.4)	33 (55)
Present	21 (35.6)	27 (45)
Arterial phase peritumoral enhancement			< 0.001*
Absent	13 (22)	42 (70)
Present	46 (78)	18 (30)
Washout			0.169
Absent	33 (55.9)	26 (43.3)
Present	26 (44.1)	34 (56.7)
Enhancing capsule			0.741
Absent	41 (69.5)	40 (66.7)
Present	18 (30.5)	20 (33.3)
Delayed central enhancement			0.404
Absent	36 (61)	41 (68.3)
Present	23 (23)	19 (31.7)
Nodule in nodule			0.144
Absent	45 (76.3)	52 (86.7)
Present	14 (23.7)	8 (13.3)
Mosaic architecture			0.303
Absent	36 (61)	42 (70)
Present	23 (39)	18 (30)
Peritumoral bile duct dilatation			0.522
Absent	52 (88.1)	55 (91.7)
Present	7 (11.9)	5 (8.3)
Hepatic capsule retraction			0.795
Absent	41 (69.5)	43 (71.7)
Present	18 (30.5)	17 (28.3)
Target sign on DWI			0.053
Absent	46 (78)	37 (61.7)
Present	13 (22)	23 (38.3)
LI-RADS categorization			0.258
LR-4/5	24 (40.7)	32 (53.4)
LR-M	30 (50.8)	26 (43.3)
LR-TIV	5 (8.5)	2 (3.3)

The data are presented as the number (%) of patients; LR-4 probably HCC, LR-5 definitely HCC, LR-M definitely or probably malignant, not HCC specific, LR-TIV tumor in vein

APHE arterial phase hyperenhancement, MVI microvascular invasion

*Means statistical significance